Want to see TSE:DTC full AI Analyst Report?
Defence Therapeutics (DTC) AI Stock Analysis
Defence Therapeutics
(CNQX:DTC)
The score is primarily constrained by weak financial performance (no revenue, recurring losses, and ongoing cash burn requiring external funding). Technicals add pressure as the stock trades below key moving averages with negative MACD and sub-50 RSI. Valuation contributes only modestly because negative earnings make P/E less meaningful and no dividend support is available.
Defence Therapeutics (DTC) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 19.70M
- Dividend Yield
- ―
- Average Volume (3M)
- 46.77K
- Price to Earnings (P/E)
- -3.2
- Beta (1Y)
- 0.25
- Revenue Growth
- ―
- EPS Growth
- -54.70%
- Country
- Canada
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Defence Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its ap...
Defence Therapeutics Financial Statement Overview
Summary
Financial profile remains weak and development-stage: no revenue across periods, recurring net losses that widened again in TTM 2026 (~-6.7M vs. ~-3.5M in 2025), and consistently negative operating/free cash flow (TTM 2026 OCF ~-4.3M; FCF ~-4.8M). A partial offset is the improved balance sheet in TTM 2026 with positive equity (~3.5M) and modest leverage (debt-to-equity ~0.29), though prior negative equity and large swings signal funding dependence.
Income Statement
12Very NegativeBalance Sheet
28NegativeCash Flow
18Very Negative| Breakdown | TTM | Jun 2026 | Sep 2025 | Jun 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -72.11K | -72.11K | -72.34K | -90.92K | -13.82K | 0 |
| EBITDA | -6.40M | -4.92M | -3.13M | -12.66M | -6.48M | 0 |
| Net Income | -6.69M | -6.70M | -3.52M | -13.19M | -6.76M | -7.34M |
Balance Sheet | ||||||
| Total Assets | 6.51M | 6.51M | 1.65M | 477.75K | 3.53M | 719.67K |
| Cash, Cash Equivalents and Short-Term Investments | 1.88M | 1.88M | 1.23M | 56.55K | 2.79M | 506.70K |
| Total Debt | 1.72M | 1.72M | 1.50M | 1.75M | 1.75M | 0 |
| Total Liabilities | 3.00M | 3.00M | 2.91M | 4.06M | 1.97M | 1.11M |
| Stockholders Equity | 3.51M | 3.51M | -1.26M | -3.58M | 1.57M | -387.56K |
Cash Flow | ||||||
| Free Cash Flow | -4.76M | -4.76M | -3.40M | -4.49M | -7.72M | -6.04M |
| Operating Cash Flow | -4.34M | -4.34M | -3.40M | -4.29M | -7.66M | -6.04M |
| Investing Cash Flow | -419.63K | -419.63K | 3,597 | -203.24K | -65.80K | 0 |
| Financing Cash Flow | 5.42M | 5.42M | 4.57M | 1.76M | 10.01M | 1.10M |
Defence Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DTC, the sentiment is Negative. The current price of 0.35 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.44, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 40.74 is Neutral, neither overbought nor oversold. The STOCH value of 4.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DTC.
Defence Therapeutics Peers Comparison
Overall Rating
TSE:MDNA43Neutral- TSE:DTC43Neutral
TSE:BCT39Underperform
TSE:BIOV28.5Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:MDNA | 43Neutral | CAD 35.32M | -2.06 | -360.29% | ― | ― | -33.27% |
| TSE:DTC | 43Neutral | CAD 26.53M | -3.17 | -424.91% | ― | ― | -54.70% |
| TSE:BCT | 39Underperform | CAD 37.55M | -0.33 | -170.70% | ― | ― | 87.90% |
| TSE:BIOV | 29Underperform | CAD 2.04M | -0.91 | 69.89% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:DTC | Defence Therapeutics Inc | 0.35 | -0.45 | -56.25% | |
| TSE:MDNA | Medicenna Therapeutics | 0.46 | -1.04 | -69.67% | |
| TSE:BCT | BriaCell Therapeutics | 4.30 | -9.65 | -69.18% | |
| TSE:BIOV | Biovaxys Technology Corp | 0.07 | -0.19 | -73.08% | |
| TSE:ONCO | Onco-Innovations Ltd. | 1.47 | 0.00 | 0.00% |
Defence Therapeutics Corporate Events
Defence Therapeutics Settles Debenture Interest in Shares and Updates Sorbie Bornholm Financing
NeutralDefence Therapeutics has issued 320,000 common shares to holders of its $2 million convertible debentures, settling $160,000 in accrued interest at an annual rate of 8 percent. The interest shares are subject to a statutory hold period of four months...
Defence Therapeutics’ Accum Platform Takes Spotlight at World ADC San Diego 2026
PositiveDefence Therapeutics has secured the Best Poster Award at World ADC San Diego 2026 for its Accum-ADC research and led a main-stage session on intracellular delivery as a key frontier for antibody-drug conjugates. The recognition underscores rising in...
Defence Therapeutics to Spotlight Accum Platform at World ADC San Diego
PositiveDefence Therapeutics will participate in the 17th World ADC San Diego conference this October, underscoring its focus on advancing antibody-drug conjugate technology through improved intracellular delivery. President and CEO Dr. Amie Phinney is sched...
Defence Therapeutics Bolsters Board With Veteran Finance Executive Sherry Aulin
PositiveDefence Therapeutics has appointed seasoned finance executive Sherry Aulin to its Board of Directors and Audit Committee, signaling a strategic strengthening of its governance and capital markets expertise. Aulin previously served as Chief Financial...
Defence Therapeutics Adds Veteran Finance Executive Sherry Aulin to Board
PositiveDefence Therapeutics has appointed veteran finance executive Sherry Aulin to its Board of Directors and Audit Committee, bolstering its governance and capital markets expertise. Aulin, a former Chief Financial Officer of Xenon Pharmaceuticals, brings...
Defence Therapeutics Advances Oncology Strategy and Tightens Leadership Alignment
PositiveDefence Therapeutics outlined progress on its strategic plan under new CEO Dr. Amie Phinney, emphasizing Accum-enhanced ADC partnerships, in-house Accum-enabled radiotherapeutics, and options for its AccuTOX program. The company is reshaping leadersh...
Defence Therapeutics Details First Settlement Under Sorbie Sharing Agreement
NeutralDefence Therapeutics has updated investors on a sharing agreement tied to a non-brokered private placement completed in March 2026, in which it raised approximately $9.6 million by issuing over 17.4 million units at $0.55 each. Of this financing, $6...
Defence Therapeutics Broadens Radiopharmaceutical Strategy with Alpha and Beta Isotope Programs
PositiveDefence Therapeutics has expanded its radiopharmaceutical development strategy to include both alpha-emitting and beta-emitting radioisotope programs, aiming to broaden the capabilities of its Accum® intracellular delivery platform. The company...
Defence Therapeutics Taps Radiopharma Veteran as COO to Drive RDC Pipeline
PositiveDefence Therapeutics has appointed Ryan Simms, PhD, as Chief Operating Officer and Head of Radiopharmaceutical Programs, reinforcing its leadership team as it advances its radiopharmaceutical drug conjugate pipeline. Simms brings more than two decade...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026